Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells
Science Advances · 17.01.2025 · 11 (3)
DOI: 10.1126/sciadv.adp9009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 17.01.2025. Verfasst von Yeye Guo und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Receptors, TNF-Related Apoptosis-Inducing Ligand, Single-Chain Antibodies, Stromal Cells. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Small extracellular vesicles (sEVs) are nanosized vesicles. Death receptor 5 (DR5) mediates extrinsic apoptosis. We engineer DR5 agonistic single-chain variable fragment (scFv) expression on the surface of sEVs derived from natural killer cells. PDGFR transmembrane domain delivers DR5-scFvs to the surface of sEVs. DR5-scFv sEVs rapidly induce apoptosis of different types of DR5 + cancer cells, myeloid-derived suppressor cells (MDSCs), and cancer-associated fibroblasts (CAFs). DR5-scFv sEVs migrate specifically to DR5 + tumors in vitro and in vivo. Systemic delivery of DR5-scFv sEVs significantly inhibits the growth of DR5 + melanoma, liver cancer, and breast cancer and prolongs mouse life span without significant toxicity. DR5-scFv sEVs are significantly more efficacious than DR5 antibodies in vivo. In organotypic patient-derived melanoma slice cultures, DR5-scFv sEVs effectively inhibit melanoma cells and MDSCs and activate CD8 + T cells. Our studies demonstrate that DR5-scFv sEVs can inhibit tumor growth by targeting tumor cells and immunosuppressive stromal cells in the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha 41000, China.
- Department of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
- Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Yeye Guo, Huaishan Wang, Shujing Liu, Xiaogang Zhang, Wenqun Zhong, Yeqing Chen, Xiang Chen, Alexander C Huang, Qiuxian Zheng, Phyllis Gimotty, Meenhard Herlyn, Wei Guo, Xiaowei Xu
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Guo, Y., Wang, H., Liu, S., Zhang, X., Zhu, X., Huang, L., Zhong, W., Guan, L., Chen, Y., Xiao, M., Ou, L., Yang, J., Chen, X., Huang, A. C., Mitchell, T., Amaravadi, R., Karakousis, G., Miura, J., Schuchter, L., …, & Xu, X. (2025). Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Science Advances, 11(3). https://doi.org/10.1126/sciadv.adp9009
Vancouver
Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, et al. Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Science Advances. 2025;11(3). doi:10.1126/sciadv.adp9009
BibTeX
@article{Guo2025,
author = {Guo, Yeye and Wang, Huaishan and Liu, Shujing and Zhang, Xiaogang and Zhu, Xingyue and Huang, Lili and Zhong, Wenqun and Guan, Lei and Chen, Yeqing and Xiao, Min and Ou, Lingling and Yang, Jingbo and Chen, Xiang and Huang, Alexander C and Mitchell, Tara and Amaravadi, Ravi and Karakousis, Giorgos and Miura, John and Schuchter, Lynn and Flowers, Ahron and Zheng, Qiuxian and Mou, Haiwei and Gimotty, Phyllis and Herlyn, Meenhard and Guo, Wei and Xu, Xiaowei},
title = {Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {3},
doi = {10.1126/sciadv.adp9009}
}
EUVIMED